CAJ | 학술논문

Objective The aim of the study was to observe the influence of autologous cytokine-induced kil er cel (CIK) treatment on the objective ef icacy and safety of gefitinib in advanced non-smal cel lung cancer (NSCLC). Methods Sixty-six patients with NSCLC received gefitinib as second-line treatment. They were randomly divided into 2 groups, and informed consent forms were signed before grouping. Gefitinib was administrat-ed to the control group, and autologous CIK treatment was added to the observation group. The objective treatment and adverse reactions were evaluated in both groups. Results The objective response rate (ORR) and the disease control rate (DCR) of the observation group were slightly higher than those of the control group, although no statistical dif erences were found between the 2 groups (P > 0.05). The incidences of diarrhea, fatigue, anorexia, oral ulcers, and myelosuppression in the observation group were much lower than those in the control group (P < 0.05). However, there were no statistical dif erences between the incidences of skin rash, and liver and kidney toxicities (P > 0.05). Conclusion Autologous CIK in combination with gefitinib is ef ective as second-line treatment for ad-vanced NSCLC, and can significantly reduce adverse reactions and improve the objective ef icacy.